Travere Therapeutics Inc
(NAS:TVTX)
$
6.4
-0.16 (-2.44%)
Market Cap: 487.23 Mil
Enterprise Value: 462.38 Mil
PE Ratio: 0
PB Ratio: 6.60
GF Score: 58/100 Travere Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Mar 15, 2023 / 03:15PM GMT
Release Date Price:
$21.27
(-2.39%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst
Good morning. My name is Carter Gould, senior biopharma analyst. Welcome to Day 2 of the Barclays Global Healthcare Conference. It's my pleasure to welcome Travere Therapeutics to the stage, right on the back end of their recent approval in IgA nephropathy.
Joining us from the company is CEO, Eric Dube; Peter Heerma, running Commercial; and Chris Cline. Guys, welcome. And also, let me offer you congratulations from me on the approval.
Eric M. Dube
Travere Therapeutics, Inc. - President, CEO & Director
Thank you very much.
Christopher Cline
Travere Therapeutics, Inc. - CFO
Thank you.
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst
I don't know if you want to make any opening comments or we can just kind of launch into Q&A.
Eric M. Dube
Travere Therapeutics, Inc. - President, CEO & Director
Yes. I mean I
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot